- Home
- SYRS
as 11-21-2024 11:39am EST
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 52.5M | IPO Year: | 2016 |
| Target Price: | $3.00 | AVG Volume (30 days): | 23.6M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.18 - $8.17 | Next Earning Date: | 10-31-2024 |
| Revenue: | $386,000 | Revenue Growth: | -95.61% |
| Revenue Growth (this year): | -96.3% | Revenue Growth (next year): | 1011.11% |
Stock Insider Trading Activity of Syros Pharmaceuticals Inc. (SYRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Quirk Gerald E | SYRS | Chief Legal & Compliance Offic | Nov 19 '24 | Sell | $0.22 | 46,657 | $10,320.53 | 0 | |
| Stephens Kristin | SYRS | Chief Development Officer | Nov 18 '24 | Sell | $0.22 | 36,133 | $7,949.26 | 0 | |
| Roth David | SYRS | Chief Medical Officer | Nov 18 '24 | Sell | $0.20 | 12,099 | $2,382.29 | 0 | |
| Chee Conley | SYRS | President & CEO | Nov 18 '24 | Sell | $0.20 | 134,797 | $26,932.44 | 0 | |
| Haas Jason | SYRS | Chief Financial Officer | Nov 18 '24 | Sell | $0.21 | 137,803 | $28,979.97 | 0 | |
| Chee Conley | SYRS | President & CEO | Sep 10 '24 | Buy | $1.61 | 100,000 | $160,680.00 | 72,504 | |
| Haas Jason | SYRS | Chief Financial Officer | Sep 10 '24 | Buy | $1.60 | 100,000 | $161,239.79 | 59,915 |
Latest Syros Pharmaceuticals Inc. News
SYRS Breaking Stock News: Dive into SYRS Ticker-Specific Updates for Smart Investing
Zacks
7 days ago
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
TipRanks
7 days ago
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
Clinical Trials Arena
8 days ago
Syros stock craters after lead cancer therapy flops in Phase III trial
Business Wire
9 days ago
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
Simply Wall St.
19 days ago
Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)
GuruFocus.com
20 days ago
Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...
Business Wire
21 days ago
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
Business Wire
a month ago
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
Compare SYRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRS Syros Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.